US examines waiver of intellectual property of COVID vaccines Coronavirus pandemic News

The White House said officials are looking at the most effective way to maximize the global outflow of vaccines.

The United States is exploring the possibility of supplying global production and supply of COVID-19 vaccines at the lowest possible cost, among other things. proposed to waive about intellectual property (IP) rights, but no decision has been made, according to the White House.

The announcement began to provide support to other U.S. and Western countries and remove export controls amid pressure from countries that are increasing deaths and infections from medical equipment and vaccine raw materials, especially India.

On Wednesday, India had more than 200,000 deaths caused by the virus, although the number is expected to be much higher.

White House spokeswoman Jen Psaki said there are “many different ways” to maximize global vaccine production.

“Right now, that’s one of the ways, but we need to assess what makes the most sense,” Psaki told reporters on Tuesday about the denial of IP rights.

It has also been done by World Health Organization officials, former world leaders and support groups call The waiver of IP rules that will allow the US and other countries with manufacturing capabilities to increase production rapidly.

Psaki said Washington officials are looking into whether it will be more effective to boost vaccine manufacturing in the U.S. Katherine Tai, the U.S. Trade Representative, added that she had not made any recommendations on the matter, and added that President Joe Biden had not made a decision.

Western countries are blocking negotiations on the WTO

The US and several other countries have so far blocked negotiations at the World Trade Organization (WTO) negotiations to deny the IP rights of pharmaceutical companies led by India and South Africa to developing countries to produce COVID-19 vaccines.

They are in favor pushing Washington will change that on April 30 before holding another WTO meeting on the issue.

Critics say that a waiver of the WTO agreement on Parties Related to Intellectual Property Trade could reduce vaccine safety, and that relocating production to new locations would undermine the resources needed to boost production at existing locations.

Tai discussed the issue on Wednesday with Pfizer and AstraZeneca PLC, and expressed interest in developing a solution that addressed critical gaps in vaccine production and distribution to developing countries.

U.S. industry leaders believe Tai Tai may be bent on saying that access to medicines from developed and developing countries is “totally unacceptable” and that the industry had to make sacrifices in times of crisis.